John Libbey Eurotext

Médecine thérapeutique / Pédiatrie

MENU

Les leucémies aiguës lymphoblastiques de l’enfant Volume 22, numéro 2, Avril-Mai-Juin 2019

  • [1] Ries LAG, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Cancer Incid Surviv Child Adolesc U S SEER Program 1975-1995 [Internet]. 1999 [cited 2019 Aug 3] ; Available from : https://www.cabdirect.org/cabdirect/abstract/20083240999.
  • [2] Lacour B., Guyot-Goubin A., Guissou S., Bellec S., Désandes E., Clavel J. Incidence of childhood cancer in France : National Children Cancer Registries, 2000-2004. Eur J Cancer Prev. 2010;19:173-181. 3
  • [3] Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18:471-484. 8
  • [4] Vijayakrishnan J., Studd J., Broderick P. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nat Commun. 2018;9:1340. 1
  • [5] Orsi L., Rudant J., Ajrouche R. Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy, and childhood acute leukemia: The ESTELLE study. Cancer Causes Control CCC. 2015;26:1003-1017. 7
  • [6] Rudant J., Lightfoot T., Urayama K.Y. Childhood acute lymphoblastic leukemia and indicators of early immune stimulation: A Childhood Leukemia International Consortium study. Am J Epidemiol. 2015;181:549-562. 8
  • [7] Wiemels J.L., Ford A.M., Van Wering E.R., Postma A., Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood. 1999;94:1057-1062. 3
  • [8] Gale K.B., Ford A.M., Repp R. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A. 1997;94:13950-13954. 25
  • [9] Mori H., Colman S.M., Xiao Z. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A. 2002;99:8242-8247. 12
  • [10] Schäfer D., Olsen M., Lähnemann D. Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood. 2018;131:821-826. 7
  • [11] Sirvent N., Suciu S., Bertrand Y., Uyttebroeck A., Lescoeur B., Otten J. Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: Results of the EORTC CLG Study 58881. Pediatr Blood Cancer. 2007;49:344-348. 3
  • [12] Teachey D.T., Pui C.-H. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20:e142-e154. 3
  • [13] Attarbaschi A., Mann G., Dworzak M., Wiesbauer P., Schrappe M., Gadner H. Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: Significance and therapy response. Med Pediatr Oncol. 2002;39:558-565. 6
  • [14] Howard S.C., Jones D.P., Pui C.-H. The Tumor Lysis Syndrome. N Engl J Med. 2011;364:1844-1854. 19
  • [15] Arber D.A., Orazi A., Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 19;127:2391-2405. 20
  • [16] Bene M.C., Castoldi G., Knapp W. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786. 10
  • [17] Tsujioka T., Sugiyama M., Ueki M. Difficulty in the diagnosis of bone and joint pain associated with pediatric acute leukemia; Comparison with juvenile idiopathic arthritis. Mod Rheumatol. 2018;28:108-113. 1
  • [18] Breatnach F., Chessells J.M., Greaves M.F. The aplastic presentation of childhood leukaemia: A feature of common-ALL. Br J Haematol. 1981;49:387-393. 3
  • [19] Hasle H., Heim S., Schroeder H., Schmiegelow K., Ostergaard E., Kerndrup G. Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL). Leukemia. 1995;9:605-608. 4
  • [20] Mandel M., Rechavi G., Neumann Y. Bone marrow cell populations mimicking common acute lymphoblastic leukemia in infants with stage IV-S neuroblastoma. Acta Haematol. 1991;86:86-89. 2
  • [21] Aida Y., Ueki T., Kirihara T. Bone marrow metastasis of rhabdomyosarcoma mimicking acute leukemia: A case report and review of the literature. Intern Med Tokyo Jpn. 2015;54:643-650. 6
  • [22] Hunger S.P., Mullighan C.G. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373:1541-1552. 16
  • [23] Lilljebjörn H., Fioretos T. New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 2017;130:1395-1401. 12
  • [24] Iacobucci I., Mullighan C.G. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35:975-983. 9
  • [25] Rubnitz J.E., Wichlan D., Devidas M. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol. 2008;26:2186-2191. 13
  • [26] Dastugue N., Suciu S., Plat G. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood. 2013;121:2415-2423. 13
  • [27] Jeha S., Pei D., Raimondi S.C. Increased risk for CNS relapse in pre-B cell leukemia with the t (1;19)/TCF3-PBX1. Leukemia. 2009;23:1406-1409. 8
  • [28] Schultz K.R., Bowman W.P., Aledo A. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol. 2009;27:5175-5181. 31
  • [29] Den Boer M.L., van Slegtenhorst M., De Menezes R.X. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol. 2009;10:125-134. 2
  • [30] Mullighan C.G., Su X., Zhang J. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-480. 5
  • [31] Lengline E., Beldjord K., Dombret H., Soulier J., Boissel N., Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98:e146-148. 11
  • [32] Reshmi S.C., Harvey R.C., Roberts K.G. Targetable kinase gene fusions in high-risk B-ALL: A study from the Children's Oncology Group. Blood. 2017;129:3352-3361. 25
  • [33] Nachman J.B., Heerema N.A., Sather H. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110:1112-1115. 4
  • [34] Moorman A.V., Ensor H.M., Richards S.M. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11:429-438. 5
  • [35] Harrison C.J., Moorman A.V., Schwab C. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome. Leukemia. 2014;28:1015-1021. 5
  • [36] Van Vlierberghe P., Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122:3398-3406. 10
  • [37] Girardi T., Vicente C., Cools J., De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017;129:1113-1123. 9
  • [38] Trinquand A., Tanguy-Schmidt A., Ben Abdelali R. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31:4333-4342. 34
  • [39] Petit A., Trinquand A., Chevret S. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131:289-300. 3
  • [40] Wood B.L., Winter S.S., Dunsmore K.P. T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome. Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. Blood. 2014;124:1-11. 21
  • [41] Patrick K., Wade R., Goulden N. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166:421-424. 3
  • [42] Smith M., Arthur D., Camitta B. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24. 1
  • [43] Domenech C., Suciu S., De Moerloose B. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014;99:1220-1227. 7
  • [44] Cavé H., van der Werff ten Bosch J., Suciu S. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998;339:591-598. 9
  • [45] Schrappe M., Valsecchi M.G., Bartram C.R. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077-2084. 8
  • [46] Farber S., Diamond L.K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787-793. 23
  • [47] Pinkel D. Five-year follow-up of “total therapy” of childhood lymphocytic leukemia. JAMA. 1971;216:648-652. 4
  • [48] Heikamp E.B., Pui C.-H. Next-generation evaluation and treatment of pediatric acute lymphoblastic leukemia. J Pediatr. 2018;203:14-24.
  • [49] Henze G., Langermann H.J., Brämswig J. The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl). Klin Padiatr. 1981;193:145-154. 3
  • [50] Fagioli F., Quarello P., Zecca M. Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: A report from the AIEOP registry. Haematologica. 2013;98:1273-1281. 8